Amarin Corporation Plc

Amarin Corp. Plc is a biopharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. Its product development program leverages its experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. It has developed and markets Vascepa capsules through wholesale. The company was founded by Geoffrey W. Guy on March 1, 1989 and is headquartered in Dublin, Ireland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Amarin reports robust Q4 earnings, eyes global expansion opportunities

Amarin's Q4 2022 earnings call highlighted strong financial performance, successful global expansion efforts, and a focus on cash preservation and talent acquisition. The company's UK launch milestones and international progress position it well for future growth.

Amarin reports Q1 revenue growth amidst pricing challenges and opportunities

Amarin focuses on revenue growth and cost-saving initiatives to drive operational efficiency and profitability.
The company's strong cash position provides stability for future growth initiatives and strategic investments.
Challenges include pricing pressure from generics and the need to balance expenses with revenue growth.
Opportunities lie in expanding prescription growth, product portfolio, and exploring strategic partnerships.

Amarin Corporation Plc reports robust Q3 earnings and strategic growth plans

Amarin Corporation Plc's Q3 2023 earnings call showcased strong financial performance, operational decisions driving positive cash flow, and a focus on maximizing shareholder value. While challenges in the European market and uncertainties around stock price were noted, opportunities for growth in global markets and strategic initiatives offer potential for future success.

Amarin reports solid Q4 revenue growth and eyes global expansion

Amarin's Q4 2023 performance reflects revenue growth and ongoing investment in strategic initiatives.
The company's strong financial position and operational momentum in key markets position it well for future growth.
Challenges around market dynamics, expenses management, and competition require strategic focus for sustained success.

Amarin reports stable Q1 earnings, focuses on European growth opportunities

Amarin Corporation's Q1 2024 earnings call highlighted solid financial performance, successful IP defense in Europe, and positive clinical outcomes for its key products. While facing challenges in the U.S. market due to generic competition, the company maintains profitability and a strong cash position. Opportunities lie in shareholder value enhancement and continued growth in Europe.

Amarin reports stable revenue but faces generic competition challenges

Amarin's Q2 2024 performance reflects revenue decline in the U.S. due to generic competition but improved net income from expense reductions. The company's strengths lie in the success of Vascepa/VAZKEPA and maintaining market share. Challenges include adapting to changing market dynamics, while opportunities exist in global expansion and strategic initiatives.

Amarin reports Q3 revenue of $42.3M, focuses on global expansion

Amarin's Q3 2024 performance reflects a mixed financial outcome with total net revenue of $42.3M and a GAAP net loss of $25.1M, impacted by challenges in the U.S. generic market.
Despite facing pricing pressures and cost reduction efforts, the company maintains a stable cash position of $306M and remains focused on global expansion.
The strengths lie in the proven science and support for VASCEPA/VAZKEPA, with opportunities to address the unmet need in reducing cardiovascular disease globally.
Challenges include navigating market dynamics and maintaining profitability amidst pricing pressures, while upcoming events signal proactive engagement for long-term value creation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amarin Corp. Plc is a pharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. It focuses on the development and commercialization of Vascepa capsules. The company was founded by Geoffrey William Guy on March 1, 1989 and is headquartered in Dublin, Ireland.

n late February, I argued that the company’s move to double its U.S. sales force to 800 to meet the demand for Vascepa, along with the future approvals of the drug in Europe, Canada and elsewhere, made Amarin stock a smart buy despite the apparent risk.

Even If It Hurts Amarin Stock, Reducing the Vascepa Sales Push Is Smart

IMAX

Roku

These companies should bounce back strong when the market finally recovers from the panic over COVID-19.

3 Stocks to Buy After the Coronavirus Crash

Amarin was supposed to have a huge 2020 after securing a key FDA approval. Instead, the stock is going down, and the CEO is selling shares.

Amarin Stock Gets Cheaper, but Serious Questions Linger

Amarin Corp. PLC (NASDAQ: AMRN) has been right in the middle of this recent market sell-off, and while shares have been halved, the stock could be poised for a strong recovery.

Is Amarin Stock Poised for a Strong Recovery?

Companies are doing everything they can to minimize in-person contact.

Amarin Pulls Back Sales Force Amid Coronavirus Pandemic

DUBLIN, Ireland and BRIDGEWATER, N.J., March  15, 2020  (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a leader in preventative cardiovascular risk reduction therapy, today announced actions in support of public health initiatives to combat the COVID-19 pandemic.

Amarin Takes Proactive Steps to Support Public Health Priorities

CRISPR Therapeutics

Amicus Therapeutics

Amicus Therapeutics, Amarin, and CRISPR Therapeutics are all way oversold.

With the Market Down, I'm Buying These 3 Stocks

An Update On Amarin's Generic Lawsuit

Amarin May Be A Bellwether In The Coronavirus Panic

If you've been waiting for a chance to buy a dip in Amarin stock, the wait is over. Here's what you need to know about the company.

Why It’s the Perfect Time to Buy Amarin Stock Now

Amarin's stock was hammered last month for two reasons.

Why Amarin Stock Plunged in February

ACADIA Pharma

Exact Sciences

Exelixis

Jazz Pharmaceuticals

Seagen

Tumultuous market conditions discounted the stock prices of these leading biotech companies.

6 Quality Biotech Stocks on Sale Now

Amarin stock has hit a wall, potentially because of generics litigation. But I think this has been an overreaction.

Amarin Stock Looks Like a Heart-Healthy Buy on the Dip

Talk about skepticism, and the effect on a company’s market capitalization and future valuation.

Amarin Stock Faces Sell-Off Crisis

Amarin stock is a risk/reward story and it offers plenty of both. It's probably best suited for investors who can deal with volatility.

Amarin Stock: When Good Results Aren’t Enough

Church & Dwight

Campbell Soup

Tuesday's big stock charts feature three big winners in Monday's big rally — all of which have hopes for further upside ahead.
The post 3 Big Stock Charts for Tuesday: Amarin, Campbell Soup, and Church & Dwight appeared first on InvestorPlace.

3 Big Stock Charts for Tuesday: Amarin, Campbell Soup, and Church & Dwight

Amarin stock has declined by nearly a quarter so far in 2020 — on little news. That lower valuation makes AMRN an intriguing candidate on the dip.

Confounding Decline Creates an Opportunity in Amarin Stock

Bank of America

Carnival

Lowe's

Amarin, Bank of America, Carnival Cruise and Lowe's were our top stock trades from Wednesday. That said, here's a look at the charts.

4 Top Stock Trades for Thursday: AMRN, LOW, BAC, CCL

Amarin stock is not reacting favorably to its earnings and revenue beat. What will it take for the stock to regain momentum?

Is It Time to Give Up on Amarin Stock After Earnings?

Amarin's (AMRN) strong revenue growth in the fourth quarter is driven by solid demand for its cardiovascular drug, Vascepa.

Amarin's (AMRN) Q4 Earnings and Sales Surpass Estimates

Amarin's strong fourth-quarter results failed to excite shareholders. Savvy investors with a long-term outlook, though, may want to buy this stock now.

Amarin: Is It Time to Test the Waters?

I’d expect based on Q3 2019 that the company will report strong revenue growth in the fourth quarter, but the real show will come in Q2 2020 and onward as Amarin's expanded salesforce meets with doctors across the country. 
The post Even Though It’s Risky, Amarin Stock Is a Worthwhile Buy appeared first on InvestorPlace.

Even Though It’s Risky, Amarin Stock Is a Worthwhile Buy

Amarin Corporation plc (AMRN) CEO John Thero on Q4 2019 Results - Earnings Call Transcript

Sales from its fish-oil derivative drug are growing significantly.

Amarin Reports Q4 Results, Beats Earnings and Revenue Targets

There’s no reason Amarin stock won’t become a big success with Vascepa, especially with access to millions of patients.
The post First-Mover Advantage Will Benefit Amarin Stock More Than You Think appeared first on InvestorPlace.

News for Amarin Corporation Plc Stock (AMRN)